相似文献
1
Lighting the path against cancer with academic light: Forty years of growth with the Chinese Medical Association-Celebrating the 110th anniversary of the founding of the Chinese Medical Association.
Cancer Pathog Ther. 2025 Jun 23;3(5):361-363. doi: 10.1016/j.cpt.2025.06.006. eCollection 2025 Sep.
2
[A century of glorious achievements and passing on the flame of medical wisdom: emotional resonance on the occasion of the 110th anniversary of the Chinese Medical Association and the National Medical Journal of China].
Zhonghua Yi Xue Za Zhi. 2025 Jul 15;105(26):2151-2153. doi: 10.3760/cma.j.cn112137-20250427-01059.
3
Letter to the Editor Regarding: "The History and Current State of Neurosurgery in the Republic of Moldova: Celebrating the 25th Anniversary of the Founding of the Department of Neurosurgery".
World Neurosurg. 2025 Feb;194:123584. doi: 10.1016/j.wneu.2024.123584. Epub 2025 Jan 13.
4
The History and Current State of Neurosurgery in the Republic of Moldova: Celebrating the 25th Anniversary of the Founding of the Department of Neurosurgery.
World Neurosurg. 2025 Jan;193:26-34. doi: 10.1016/j.wneu.2024.10.004. Epub 2024 Oct 28.
5
Unveiling the link between self-regulated learning and academic success: a longitudinal study on Chinese medical students.
Adv Health Sci Educ Theory Pract. 2024 Dec 2. doi: 10.1007/s10459-024-10400-9.
6
: celebrating 10 years of publishing excellence: a decade in review.
BJPsych Open. 2025 Aug 13;11(5):e179. doi: 10.1192/bjo.2025.10773.
7
Workplace lighting for improving alertness and mood in daytime workers.
Cochrane Database Syst Rev. 2018 Mar 2;3(3):CD012243. doi: 10.1002/14651858.CD012243.pub2.
8
Efficacy and safety of warming Yang and dredging intestines method in metastatic colon cancer maintenance.
World J Clin Oncol. 2025 Jun 24;16(6):105175. doi: 10.5306/wjco.v16.i6.105175.
9
Cycled light in the intensive care unit for preterm and low birth weight infants.
Cochrane Database Syst Rev. 2013 Aug 3(8):CD006982. doi: 10.1002/14651858.CD006982.pub3.
10
[From the integration of the internet and medicine to the synergy of artificial intelligence and medicine: my perspective on "future medicine" and the development of medical education].
Zhonghua Yi Xue Za Zhi. 2025 Aug 5;105(29):2437-2439. doi: 10.3760/cma.j.cn112137-20250417-00956.
本文引用的文献
1
Efficacy and safety of bevacizumab biosimilar SIBP04 compared with bevacizumab (Avastin®) as first-line treatment for locally advanced or metastatic non-squamous non-small-cell lung cancer: A randomized, double-blind, phase 3 trial.
Cancer Pathog Ther. 2025 Jan 6;3(4):337-345. doi: 10.1016/j.cpt.2025.01.001. eCollection 2025 Jul.
2
Efficacy and safety of limertinib versus gefitinib as first-line treatment for locally advanced or metastatic non-small-cell lung cancer with EGFR-sensitising mutation: a randomised, double-blind, double-dummy, phase 3 trial.
Lancet Respir Med. 2025 Jun 20. doi: 10.1016/S2213-2600(25)00121-3.
3
First-line treatment of anti-EGFR monoclonal antibody cetuximab β plus FOLFIRI versus FOLFIRI alone in Chinese patients with RAS/BRAF wild-type metastatic colorectal cancer: a randomized, phase 3 trial.
Signal Transduct Target Ther. 2025 May 7;10(1):147. doi: 10.1038/s41392-025-02229-4.
4
Rezivertinib versus gefitinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer (REZOR): a multicentre, double-blind, randomised, phase 3 study.
Lancet Respir Med. 2025 Apr;13(4):327-337. doi: 10.1016/S2213-2600(24)00417-X. Epub 2025 Feb 3.
5
Glecirasib in KRAS-mutated nonsmall-cell lung cancer: a phase 2b trial.
Nat Med. 2025 Mar;31(3):894-900. doi: 10.1038/s41591-024-03401-z. Epub 2025 Jan 6.
6
Finotonlimab with chemotherapy in recurrent or metastatic head and neck cancer: a randomized phase 3 trial.
Nat Med. 2024 Sep;30(9):2568-2575. doi: 10.1038/s41591-024-03110-7. Epub 2024 Jun 28.
7
Iruplinalkib (WX-0593) Versus Crizotinib in ALK TKI-Naive Locally Advanced or Metastatic ALK-Positive NSCLC: Interim Analysis of a Randomized, Open-Label, Phase 3 Study (INSPIRE).
J Thorac Oncol. 2024 Jun;19(6):912-927. doi: 10.1016/j.jtho.2024.01.013. Epub 2024 Jan 25.
8
Efficacy and safety of KL-A167 in previously treated recurrent or metastatic nasopharyngeal carcinoma: a multicenter, single-arm, phase 2 study.
Lancet Reg Health West Pac. 2022 Oct 10;31:100617. doi: 10.1016/j.lanwpc.2022.100617. eCollection 2023 Feb.
9
Comparison of efficacy and safety of ripertamab (SCT400) versus rituximab (Mabthera ) in combination with CHOP in patients with previously untreated CD20-positive diffuse large B-cell lymphoma: A randomized, single-blind, phase III clinical trial.
Hematol Oncol. 2022 Dec;40(5):930-940. doi: 10.1002/hon.3054. Epub 2022 Aug 12.
10
Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study.
Lancet Respir Med. 2022 Nov;10(11):1019-1028. doi: 10.1016/S2213-2600(22)00168-0. Epub 2022 Jun 2.
Zotero 插件